<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1858">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136976</url>
  </required_header>
  <id_info>
    <org_study_id>19PH226</org_study_id>
    <secondary_id>2021-000009-25</secondary_id>
    <nct_id>NCT05136976</nct_id>
  </id_info>
  <brief_title>Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders</brief_title>
  <acronym>THERAMAG</acronym>
  <official_title>Rituximab Therapy in Anti-MAG Patients With Characteristics of Good Responders:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-MAG neuropathy is a progressively disabling orphan rare disorder due to a monoclonal&#xD;
      immunoglobulin M(IgM) gammopathy displaying reactivity toward MAG, a glycoprotein of the&#xD;
      peripheral nervous system. Its prevalence is around 1/100000 and to date, no treatment has&#xD;
      proven efficacy in this disease, including rituximab in 2 Randomized Controlled Trails(RCTs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      However these trials have included unselected anti-MAG patients and methodological issues&#xD;
      have been raised.&#xD;
&#xD;
      In COFRAMAG study, the largest cohort worldwide of anti-MAG patients we published recently,&#xD;
      predictors of clinical response to rituximab were identified through analysis of 92 treated&#xD;
      patients: shorter disease duration and anti-MAG titre above 10000 BTU. Thus this study will&#xD;
      focus on rituximab efficacy in a subset of patients with disease duration of less than 2&#xD;
      years and anti-MAG titre above 10000 Buhlmann Titer Units (BTU). We selected Inflammatory&#xD;
      Rasch-built Overall Disability Scale (I-RODS) as primary outcome measure because its&#xD;
      responsiveness was proven higher than INCAT/ Overall Neuropathy Limitation Score (ONLS)&#xD;
      scales to detect clinical meaningful changes in newly treated patients with inflammatory&#xD;
      neuropathies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2022</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The THERAMAG study is a French academic multicentre, randomized, double-blind trial sponsored by the University Hospital of Saint-Etienne, comparing rituximab infusion to placebo infusion in anti-MAG patients presumed as good clinical responders.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The randomization will be performed by the pharmacy. The treatment group will not be mentioned to the clinicians.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis clinical response by I-RODS results</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Clinical response defined as a 4 points (or more) increase of I-RODS between baseline and 12 months.&#xD;
I-RODS is a 24-item patient-reported outcome measure which maximum score is 48. It is a linearly weighted scale that specifically captures activity and social participation limitations in patients with inflammatory neuropathies, including Monoclonal Gammopathy of Unknown Significance (MGUS) related polyneuropathies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Neuropathy Cause and Treatment (INCAT) disability score</measure>
    <time_frame>Months: 0, 6, 12</time_frame>
    <description>The INCAT (Inflammatory Neuropathy Cause and Treatment) disability score is a measure of activity limitation with minimum score at 0 and maximum at 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six minute walk test</measure>
    <time_frame>Months : 0, 6, 12</time_frame>
    <description>Six minute walk test will be realized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed 25- foot walk (FW) test</measure>
    <time_frame>Months : 0, 6, 12</time_frame>
    <description>The T25-FW is a quantitative test of mobility and performance of leg function based on a timed outward journey of 25 steps, and a timed return journey of 25 steps. The score for the T25-FW is the average of the two completed trials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9 hole peg test</measure>
    <time_frame>Months : 0, 6, 12</time_frame>
    <description>The nine hole peg test is a standardized, quantitative assessment used to measure finger dexterity. Scores are based on the time taken to complete the test activity, recorded in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ElectroNeuroMyography (ENMG) motor sum score</measure>
    <time_frame>Months : 0, 6, 12</time_frame>
    <description>ENMG motor sum score will be realized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ENMG sensory sum score</measure>
    <time_frame>Months : 0, 6, 12</time_frame>
    <description>ENMG sensory sum score will be realized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score Motor unit number index (MUNIX)</measure>
    <time_frame>Months : 0, 6, 12</time_frame>
    <description>Score MUNIX will be realised.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the short-term safety and tolerability of Rituximab</measure>
    <time_frame>Months : 0, 6, 12</time_frame>
    <description>Consideration of adverse effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the anti-MAG antibody titre.</measure>
    <time_frame>Months : 0, 6, 12</time_frame>
    <description>To study the correlation between the clinical response and the evolution of the anti-MAG antibody titre.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Anti-MAG Neuropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient with anti-MAG neuropathy will be included. They will randomized in placebo or Rituximab group.&#xD;
They will have the same premedications prior to rituximab or placebo infusions:&#xD;
IV Dexchlorpheniramine Maleate IV: 10 mg&#xD;
IV Methylprednisolone: 40 mg&#xD;
PO Paracetamol : 1 gram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient with anti-MAG neuropathy will be included. They will randomized in placebo or Rituximab group.&#xD;
They will have the same premedications prior to rituximab or placebo infusions:&#xD;
IV Dexchlorpheniramine Maleate IV: 10 mg&#xD;
IV Methylprednisolone: 40 mg&#xD;
PO Paracetamol : 1 gram</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab infusion</intervention_name>
    <description>2 infusions of 1 gram of rituximab at a 2 week interval (day 1 followed by day 15).</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>2 infusions of placebo at a 2 week interval.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium chloride (NaCl)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premedications</intervention_name>
    <description>Premedications prior to rituximab or placebo infusions:&#xD;
IV Dexchlorpheniramine Maleate IV: 10 mg&#xD;
IV Methylprednisolone: 40 mg&#xD;
PO Paracetamol : 1 gram</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease duration of 24 months or less and documented clinical worsening (clinical or&#xD;
             ENMG or disability) over the past 12 months&#xD;
&#xD;
          -  IgM gammopathy, either MGUS or Waldenstrom Macroglobulinemia (WM)&#xD;
&#xD;
          -  Demyelinating polyneuropathy according to European Federation of Neurological&#xD;
             Societies/Peripheral Nerve Society guidelines for chronic inflammatory demyelinating&#xD;
             polyneuropathy on nerve conduction studies.&#xD;
&#xD;
          -  Anti-MAG titre of 10 000 BTU or more&#xD;
&#xD;
          -  Total INCAT score of 1 point or more at baseline&#xD;
&#xD;
          -  Absence of immunoglobulin treatment within 3 months prior to inclusion.&#xD;
&#xD;
          -  Absence of immunosuppressive therapy within 6 months prior to inclusion, including&#xD;
             steroid therapy of 2 months or more as part of the management of neuropathy.&#xD;
&#xD;
          -  Negative β-human chorionic gonadotropin (HCG) in women of childbearing potential&#xD;
&#xD;
          -  Women of childbearing potential must agree to use contraception for 365 days following&#xD;
             administration of rituximab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Unable to give informed consent&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reaction to chimeric monoclonal antibody&#xD;
&#xD;
          -  Hypersensitivity known to one of the compounds of polaramine or methylprednisolone&#xD;
&#xD;
          -  Previous treatment with rituximab&#xD;
&#xD;
          -  Diseases known to cause polyneuropathy (e.g. diabetes, uncontrolled thyroid disease,&#xD;
             vitamin B1 or B12 deficiency, renal (GFR &lt; 60ml ml/min/1,73 m2- Modification of Diet&#xD;
             in Renal Disease (MDRD) formula) or liver disorder, myeloma, amyloidosis,&#xD;
             cryoglobulinemia)&#xD;
&#xD;
          -  Indication of specific immunosuppressive therapy for WM&#xD;
&#xD;
          -  Significant uncontrolled disease at baseline such as cardiovascular (including cardiac&#xD;
             arrhythmia), pulmonary (including obstructive pulmonary disease), renal, hepatic,&#xD;
             endocrine or gastrointestinal or any other significant disease that may prevent&#xD;
             patient from participating in the study&#xD;
&#xD;
          -  Congestive heart failure (NYHA III or IV)&#xD;
&#xD;
          -  Known active bacterial, viral, fungal mycobacterial infection&#xD;
&#xD;
          -  History or known presence of recurrent or chronic infection (e.g. viral hepatitis, HIV&#xD;
             syphilis, tuberculosis).&#xD;
&#xD;
          -  History of cancer, including solid tumors and haematological malignancies (except&#xD;
             basal cell and in situ squamous carcinoma of the skin, in situ carcinoma of the cervix&#xD;
             of the uterus that have been excised and resolved, with documented clear margins on&#xD;
             pathology)&#xD;
&#xD;
          -  History of alcohol (more than two drinks a day for a woman, more than 4 glasses a day&#xD;
             for a man [World Health Organization (WHO) definition]) or other drug abuse within 6&#xD;
             months prior to randomization&#xD;
&#xD;
          -  History or currently active primary or secondary immunodeficiency&#xD;
&#xD;
          -  White blood cell count &lt; 1500/mm3 or platelet count &lt; 75 000/mm3&#xD;
&#xD;
          -  Angle closure glaucoma,&#xD;
&#xD;
          -  Urinary retention related to urethroprostatic disorders,&#xD;
&#xD;
          -  Uncontrolled psychotic disorders,&#xD;
&#xD;
          -  Severe liver failure,&#xD;
&#xD;
          -  Recent vaccination with live vaccines (&lt;3months) and vaccination with live virus&#xD;
             vaccines is not recommended during the overall study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Laure KAMINSKY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Laure KAMINSKY, MD</last_name>
    <phone>(0)4 77 82 95 10</phone>
    <phone_ext>+33</phone_ext>
    <email>a.laure.kaminsky@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carine LABRUYERE, CRA</last_name>
    <phone>(0)4 77 12 04 69</phone>
    <phone_ext>+33</phone_ext>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Brest - La cavale blanche</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jean-Baptiste NOURY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble - La tronche</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Martial MALLARET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille - Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Céline TARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges - Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87170</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Laurent MAGY, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Juliette SVAHN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Timone - APHM</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Shahram Attarian, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy- Hôpital central</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Maud MICHAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice - Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06031</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Sabrina SACCONI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Thierry MAISONOBE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Kremlin-Bicêtre</name>
      <address>
        <city>Paris</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Andoni ECHANIZ-LAGUNA, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Anne-Laure KAMINSKY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg - Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jean-Baptiste CHANSON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Pierre-Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Pascal CINTAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Philippe CORCIA, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropathy</keyword>
  <keyword>Anti-MAG</keyword>
  <keyword>Rituximab</keyword>
  <keyword>I-RODS</keyword>
  <keyword>placebo</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

